Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.46 |
| ▸ | WNT3A | P56704 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359111 | 0.81 | GSK3B (0.52) | KMT2AGSK3BMEN1CES2CES1 | |
| SCHEMBL104262 | 0.81 | GSK3B (0.53) | KMT2AGSK3BPKMMEN1NPC1 | |
| SCHEMBL904220 | 0.81 | TDP1 (0.55) | KMT2AGSK3BMEN1NPC1RAB9A | |
| SCHEMBL16552778 | 0.80 | KMT2A (0.83) | KMT2AGSK3BPKMMEN1NPC1 | |
| SCHEMBL9419411 | 0.76 | KMT2A (0.69) | KMT2AGSK3BMEN1NPC1RAB9A | |
| SCHEMBL903614 | 0.75 | THRA (0.65) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8402203 | 0.74 | KMT2A (0.67) | KMT2AGSK3BMEN1NPC1RAB9A | |
| SCHEMBL10854341 | 0.74 | KMT2A (0.67) | KMT2AGSK3BMEN1NPC1RAB9A | |
| SCHEMBL8750840 | 0.74 | KMT2A (0.67) | KMT2AGSK3BMEN1NPC1RAB9A | |
| SCHEMBL507742 | 0.74 | HSD17B3 (0.69) | KMT2AGSK3BMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621886-B1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON BV (NL) | 2018-05-02 | — | — | EP | disclosed |
| WO-2015107548-A1 | IMPROVED FINGOLIMOD PROCESS | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-07-23 | — | — | WO | disclosed |
| US-8735627-B2 | Intermediate compounds and process for the preparation of fingolimod | MAPI PHARMA LTD. (IL) | 2014-05-27 | — | — | US | disclosed |
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | MAPI PHARMA LTD. (IL) | 2013-08-22 | — | — | US | disclosed |
| WO-2012041359-A1 | PROCESS FOR MAKING FINGOLIMOD | SYNTHON B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217899-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF FINGOLIMOD | S1PR2, S1PR4, S1PR3 | KMT2A 1011/4885GSK3B 1509/4885PKM 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.